GlassScriptPhysician profile
Nicholas Steckler
NPI 1801386578
$7,428.78
in general payments reported to CMS, 2019-2025
45 companies · $1,683 in 2025
The $1,683 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $417 · 2022: $1,719 · 2023: $1,881 · 2024: $1,729 · 2025: $1,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,293.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $983.10 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $651.82 | 2021-2025 | Evenity, Otezla, Repatha |
| Abbvie INC. | $612.71 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Lilly USA, LLC | $594.49 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $509.60 | 2022-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $474.18 | 2021-2025 | Airsupra, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $405.26 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $247.99 | 2021-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $245.80 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $213.03 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $211.15 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $200.39 | 2022-2025 | Xifaxan, Trulance |
| Pfizer INC. | $199.77 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $120.99 | 2023-2025 | Rexulti, Nuedexta |
| Astellas Pharma US INC | $115.52 | 2024-2025 | Veozah |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $111.99 | 2022 | |
| Exact Sciences Corporation | $109.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi-Aventis U.S. LLC | $103.22 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $94.16 | 2024-2025 | Voquezna |
| Melinta Therapeutics, LLC | $86.64 | 2023 | Kimyrsa |
| Dexcom, INC. | $86.32 | 2021-2023 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $79.21 | 2021-2025 | Gvoke Hypopen, Keveyis |
| Eisai INC. | $77.71 | 2021-2025 | |
| Ultragenyx Pharmaceutical INC. | $72.09 | 2022-2023 | Crysvita |
| Axsome Therapeutics, INC. | $70.35 | 2022-2025 | Auvelity |
| Corcept Therapeutics | $70.27 | 2024 | Korlym |
| Abbott Laboratories | $62.93 | 2023-2025 | Freestyle Libre 3, Octrode |
| Mannkind Corporation | $59.40 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.33 | 2025 | Caplyta |
| Medtronic, INC. | $56.95 | 2023-2024 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.38 | 2021-2025 | Jardiance |
| Sumitomo Pharma America, INC. | $53.68 | 2024-2025 | Gemtesa |
| Mckesson Medical-Surgical, INC. | $50.14 | 2025 | |
| Idorsia Pharmaceuticals US INC | $44.78 | 2022-2023 | Quviviq |
| Lundbeck LLC | $44.09 | 2023-2025 | Rexulti |
| Seqirus USA INC | $26.82 | 2022-2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Alexion Pharmaceuticals, INC. | $24.75 | 2022 | |
| Esperion Therapeutics, INC. | $24.59 | 2023 | Nexletol |
| Genzyme Corporation | $22.78 | 2023 | |
| Grifols USA, LLC | $22.53 | 2022 | |
| Boston Scientific Corporation | $19.56 | 2024 | General Dbs |
| Teva Pharmaceuticals USA, INC. | $17.53 | 2022 | |
| Upsher-Smith Laboratories LLC | $15.33 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.51 | 2025 | Zoryve |
| Inogen, INC. | $9.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Steckler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.